Ex-vivo perfusion has become standard of preservation for a variety of solid organs. The main purpose for this technology has been extension of maximum allowable ischemia time. A variety of technological setups have successfully been developed and introduced into clinical applications, such as hypothermic, sub-normothermic as well as normothermic perfusion systems in combination with a variety of different perfusion solutions.
Recently, organ ex vivo perfusion showed to be an excellent administration route of drug-, cell- and gene- therapeutic agents that might engineer the graft properties towards supporting graft function and survival after allogeneic and xenogeneic transplantation.
These perfusion platforms technically also allow for graft treatments and modifications prior to transplantation. Potential modifications comprise areas of reduction of ischemia-reperfusion injury, treatment of prior impaired organ conditions or attenuation of immunogenicity. This research topic aims at elucidating the state of the art of ex-vivo graft preservation and modification laying the foundation for the extension of applications within the transplantation community.
We welcome original research, case reports/series, review articles and opinion/perspective pieces on:
- Ex-vivo perfusion technology
- Ex-vivo graft conditioning
- Ex-vivo graft modification
- Ex-vivo graft repair
- Translation from experimental to clinical application
- Novel therapeutics and pharmacological agents
- Allogeneic transplantation
- Xenogeneic transplantation
Ex-vivo perfusion has become standard of preservation for a variety of solid organs. The main purpose for this technology has been extension of maximum allowable ischemia time. A variety of technological setups have successfully been developed and introduced into clinical applications, such as hypothermic, sub-normothermic as well as normothermic perfusion systems in combination with a variety of different perfusion solutions.
Recently, organ ex vivo perfusion showed to be an excellent administration route of drug-, cell- and gene- therapeutic agents that might engineer the graft properties towards supporting graft function and survival after allogeneic and xenogeneic transplantation.
These perfusion platforms technically also allow for graft treatments and modifications prior to transplantation. Potential modifications comprise areas of reduction of ischemia-reperfusion injury, treatment of prior impaired organ conditions or attenuation of immunogenicity. This research topic aims at elucidating the state of the art of ex-vivo graft preservation and modification laying the foundation for the extension of applications within the transplantation community.
We welcome original research, case reports/series, review articles and opinion/perspective pieces on:
- Ex-vivo perfusion technology
- Ex-vivo graft conditioning
- Ex-vivo graft modification
- Ex-vivo graft repair
- Translation from experimental to clinical application
- Novel therapeutics and pharmacological agents
- Allogeneic transplantation
- Xenogeneic transplantation